Antitubercular activity and the subacute toxicity of (-)-licarin a in balb/c mice: A neolignan isolated from aristolochia taliscana

Archives of Medical Research

Volumn 44, Issue 2, 2013, Pages 99-104

  León Díaz, Rosalba ^a   Meckes Fischer, Mariana ^b   Valdovinos Martínez, Luis ^a   Campos, María G ^a   Hernández Pando, Rogelio ^c   Jiménez Arellanes, María Adelina ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Cedimemm Centro de Diagnóstico en Metabolismo Energético y Medicina Mitocondrial   (Mexico)

^c SECRETARÍA DE SALUD   (Mexico)

Author keywords

( ) Licarin A; MDR; Mycobacterium tuberculosis; Subacute toxicity; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARISTOLOCHIA TALISCANA EXTRACT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LICARIN A; NEOLIGNAN; PLANT EXTRACT; TRIACYLGLYCEROL; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; URIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARISTOLOCHIA; ARISTOLOCHIA TALISCANA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL LOAD; CHOLESTEROL BLOOD LEVEL; COLONY FORMING UNIT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG ISOLATION; ERYTHROCYTE COUNT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; THROMBOCYTE COUNT; TOXICITY TESTING; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANIMALS; ANTITUBERCULAR AGENTS; ARISTOLOCHIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; LIGNANS; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84875274605     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.12.006     Document Type: Article

References (25)

1. Ralph A.P., Anstey N.M., Kelly P.M. Tuberculosis into the 2010s: is the glass half full?. Clin Infect Dis 2009, 49:574-583.
2. WHO Report 2010 2010, Global Tuberculosis Control, World Health Organization, Geneva, Switzerland.
3. Raviglione M.C., Smith I.M. XDR tuberculosis-implications for global public health. N Engl J Med 2007, 356:656-659.
4. Koul A., Arnoult E., Lounis N., et al. The challenge of new drug discovery for tuberculosis. Nature 2011, 469:483-490.
5. Rivers E.C., Mancera R.L. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today 2008, 13:1090-1098.
6. Hernández-Pando R., Aguilar-Leon D., Orozco H., et al. 16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. J Infect Dis 2005, 191:299-306.
7. Huerta-Yepez S., Baay-Guzman G.J., Garcia-Zepeda R., et al. 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol 2008, 129:313-324.
8. Abe F., Nagafuji S., Yamauchi T., et al. Trypanocidal constituents in plants. 1. Evaluation of some Mexican plants for their trypanocidal activity and active constituents in guaco roots of Aristolochia taliscana. Biol Pharm Bull 2002, 25:1188-1191.
9. Lee S.U., Shim K.S., Ryu S.Y., et al. Machilin A isolated from Myristica fragrans stimulates osteoblast differentiation. Planta Med 2009, 75:152-157.
10. Ma C.J., Kim S.R., Kim J., et al. Meso-dihydroguaiaretic acid and licarin A of Machilus thunbergii protect against glutamate-induced toxicity in primary cultures of a rat cortical cells. Br J Phamacol 2005, 146:752-759.
11. Park B.Y., Min B.S., Kwon O.K., et al. Increase of caspase-3 activity by lignans from Machilus thunbergii in HL-60 cells. Biol Pharm Bull 2004, 27:1305-1307.
12. León-Díaz R., Meckes M., Said-Fernández S., et al. Antimycobacterial neolignans isolated from Aristolochia taliscana. Mem Inst Oswaldo Cruz 2010, 105:45-51.
13. Enríquez R.G., Chávez M.A., Reynolds W.F. Phytochemical investigations of plants of the genus Aristolochia. 1. Isolation and NMR spectral characterization of eupomatenoid derivatives. J Nat Prod 1984, 47:896-899.
14. NORMA Oficial Mexicana NOM-062-ZOO-1999 revisado y publicado el 08-08-2011, Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. Diario Oficial de la Federación.
15. Hernández-Pando R., Orozco-Esteves H., Maldonado H.A., et al. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol 2006, 144:264-272.
16. Molina-Salinas G.M., Bórquez J., Said-Fernández S., et al. Antituberculosis activity of alkylated mulinane diterpenoids. Fitoterapia 2010, 81:219-222.
17. Copp B.R., Pearce A.N. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat Prod Rep 2007, 24:278-297.
18. Murakami Y., Shoji M., Hirata A., et al. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys 2005, 15:326-332.
19. Fujisawa S., Ishihara M., Murakami Y., et al. Predicting the biological activities of 2-methoxyphenol antioxidants: effects of dimers. In Vivo 2007, 21:181-188.
20. van Soolingen D., Hernández-Pando R., Orozco H., et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010, 5:e12640.
21. 37Rv, MDR and NRP Mycobacterium tuberculosis. Bioorg Med Chem 2009, 17:503-511.
22. Rangel-Moreno J., Estrada-García I., García-Hernández M.L., et al. The role of protaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 2002, 106:257-266.
23. Hernandez-Pando R., Rook G.A. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994, 82:591-595.
24. van den Boogaard J., Kibiki G.S., Kisanga E.R., et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009, 53:849-862.
25. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis 2006, World Health Organization, Geneva.